Increased Fatigue May Predict CLL Disease Progression
October 11, 2024
Based on outcomes reported by patients, increased fatigue may predict disease progression in relapsed CLL / SLL patients on ibrutinib or zanubrutinib.
Based on outcomes reported by patients, increased fatigue may predict disease progression in relapsed CLL / SLL patients on ibrutinib or zanubrutinib.
Fatigue is one of the most common symptoms experienced by those living with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), and it is also commonly overlooked, underreported, and undertreated.
Fatigue is one of the most common symptoms experienced by those living with CLL and SLL, and it is also commonly overlooked,underreported, and undertreated.
Ask the Doctor Question: I was diagnosed with CLL in 2015 and on watch and wait, with good bloods. I am Stage A/0. I was a Specialist Biomedical Scientist in the
March 2026 CLL Bloodline: The CLL Society Bloodline will teach the BASICS needed to understand CLL.
Half of patients with Richter transformation responded to treatment with epcoritamab, and outcomes were even better when it was used as a first-line therapy.
Rocbrutinib appears to be effective in CLL patients with prior exposure to covalent and noncovalent BTKi, and it is generally well-tolerated.
In a phase 1 trial, BTK degrader bexobrutideg produced very good response rates in heavily pretreated patients with CLL / SLL and was generally well-tolerated.
CLL patients often have suboptimal COVID-19 vaccine responses and worse outcomes. GEO-CM04S1, a new type of vaccine, results in stronger T cell immunity.